Maxymune Therapeutics, Inc.

LOS ALTOS, CA · Founded 2023 · Biotech · Private

Immunological disorder therapeutics using novel biological mechanisms

Claim this profile

Follows are private to you and power your alerts

Updated · maxymunetx.com

Sector
Biotech
Headquarters
LOS ALTOS, CA
Founded
2023
Latest Form D
$850K, Feb 2025
Total capital
$850K
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$850K
1 Form D · last Feb 2025
20 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
2 pending · first 2025
Rank in peer group#481 of 1449

Capital timeline

2025FEDERAL ↑EQUITY ↓Cumulative $850K1st Form D$850K
2025FEDERAL ↑EQUITY ↓Cumulative $850K1st Form D$850K

Latest events

  • Private capital raisedForm D · SEC · 1st filing$850K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#481 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Gordon RingoldExecutive Officer, DirectorNamed in SEC Form D filings
  • Neil SolomonsDirectorNamed in SEC Form D filings
  • Tatjana NarandaExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 3
  • PendingPhenylalanine-based LAT1 Inhibitors And Uses ThereofUSPTOApplication 19264497
  • GrantedPhenylalanine-based LAT1 Inhibitors And Uses ThereofUSPTOUS 12,427,124
  • PendingPhenylalanine-based LAT1 Inhibitors And Uses ThereofUSPTOApplication PCTUS2025017195

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .